Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06104839
PHASE2
Safety and Efficacy of Oral NXC-736 in Adult Participants with Moderate and Severe Alopecia Areata
Sponsor: NEXTGEN Bioscience
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients with Moderate and Severe Alopecia Areata
Key Details
Gender
All
Age Range
19 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2024-09-01
Completion Date
2025-06-30
Last Updated
2024-12-17
Healthy Volunteers
No
Conditions
Interventions
DRUG
NXC736
oral administration
DRUG
Placebo
oral administration
Locations (2)
Seoul National University Hospital.
Seoul, South Korea
Kyung Hee University Hospital at Gangdong
Seoul, South Korea